Etomidate derivatives: Novel pharmaceutical agents in anesthesia

Raymond J Malapero, Michael P Zaccagnino, Ethan Y Brovman, Alan David Kaye, Richard D Urman, Raymond J Malapero, Michael P Zaccagnino, Ethan Y Brovman, Alan David Kaye, Richard D Urman

Abstract

Etomidate is an imidazole derivative that possesses important sedative properties employed in anesthesia practice, however, etomidate has a number of well-know side effects which limit its use in certain subpopulations and over long periods of time, mostly related to dose-dependent adrenal suppression. This review focuses on novel etomidate derivatives with an emphasis on pharmacological properties which afford improved safety profile and potentially desirable clinical effects. The pharmacology and clinical investigation of some of these etomidate derivatives, e.g. cyclopropyl-methoxycarbonyl, carboetomidate metomidate, methoxycarbonyl-etomidate, cyclopropyl-methoxycarbonyl metomidate (CPMM), and dimethyl-methoxycarbonyl metomidate, are discussed in detail. The increased potency and decreased metabolite build-up of CPMM potentially makes it a very favorable drug, particularly in the setting of prolonged infusions. Further, when compared with etomidate, CPMM produces lower plasma cytokine concentration and improved survival in lipopolysaccharide inflammatory sepsis models.

Keywords: Adrenal suppression; carboetomidate metomidate; cyclopropyl-methoxycarbonyl; cyclopropyl-methoxycarbonyl metomidate; dimethyl-methoxycarbonyl metomidate; etomidate; imidazole; methoxycarbonyl-etomidate.

Conflict of interest statement

There are no conflicts of interest.

References

    1. Bergen JM, Smith DC. A review of etomidate for rapid sequence intubation in the emergency department. J Emerg Med. 1997;15:221–30.
    1. Reves JG, Glass PS, Lubarsky DA, McEvoy MD. Miller's Anesthesia. 6th ed. Philadelphia: Elsevier Churchill; 2005. Intravenous nonopioid anesthetics.
    1. Forman SA. Clinical and molecular pharmacology of etomidate. Anesthesiology. 2011;114:695–707.
    1. Butterworth J, Mackey D. Morgan & Mikhail's Clinical Anesthesiology. 5th ed. New York: McGraw-Hill; 2013. Intravenous anesthetics.
    1. Jabre P, Combes X, Lapostolle F, Dhaouadi M, Ricard-Hibon A, Vivien B, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: A multicentre randomised controlled trial. Lancet. 2009;374:293–300.
    1. Rech MA, Bennett S, Chaney W, Sterk E. Risk factors for mortality in septic patients who received etomidate. Am J Emerg Med. 2015;33:1340–3.
    1. Voss LJ, Sleigh JW, Barnard JP, Kirsch HE. The howling cortex: Seizures and general anesthetic drugs. Anesth Analg. 2008;107:1689–703.
    1. Longnecker D. Anesthesiology. New York: McGraw-Hill, Medical Pub.; Division; 2008. Pharmacology of intravenous anesthetics.
    1. Chitilian HV, Eckenhoff RG, Raines DE. Anesthetic drug development: Novel drugs and new approaches. Surg Neurol Int. 2013;4((Suppl 1)):S2–S10.
    1. Pejo E, Feng Y, Chao W, Cotten JF, Le Ge R, Raines DE. Differential effects of etomidate and its pyrrole analogue carboetomidate on the adrenocortical and cytokine responses to endotoxemia. Crit Care Med. 2012;40:187–92.
    1. Jackson WL., Jr Carboetomidate: Will it eliminate the etomidate debate? Crit Care Med. 2012;40:333–4.
    1. Desai R, Miller KW, Raines DE. The pyrrole etomidate analog carboetomidate potently inhibits human 5-HT3A receptor function: Comparisons with etomidate and potential implications for emetogenesis. Anesth Analg. 2013;116:573–9.
    1. Cotten JF, Husain SS, Forman SA, Miller KW, Kelly EW, Nguyen HH, et al. Methoxycarbonyl-etomidate: A novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. Anesthesiology. 2009;111:240–9.
    1. Pejo E, Cotten JF, Kelly EW, Le Ge R, Cuny GD, Laha JK, et al. In vivo and in vitro pharmacological studies of methoxycarbonyl-carboetomidate. Anesth Analg. 2012;115:297–304.
    1. Shanmugasundararaj S, Zhou X, Neunzig J, Bernhardt R, Cotten JF, Ge R, et al. Carboetomidate: An analog of etomidate that interacts weakly with 11ß-hydroxylase. Anesth Analg. 2013;116:1249–56.
    1. Ge R, Pejo E, Husain SS, Cotten JF, Raines DE. Electroencephalographic and hypnotic recoveries after brief and prolonged infusions of etomidate and optimized soft etomidate analogs. Anesthesiology. 2012;117:1037–43.
    1. Ge R, Pejo E, Gallin H, Jeffrey S, Cotten JF, Raines DE. The pharmacology of cyclopropyl-methoxycarbonyl metomidate: A comparison with propofol. Anesth Analg. 2014;118:563–7.
    1. Campagna JA, Pojasek K, Grayzel D, Randle J, Raines DE. Advancing novel anesthetics: Pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs. Anesthesiology. 2014;121:1203–16.
    1. Santer P, Pejo E, Feng Y, Chao W, Raines DE. Cyclopropyl-methoxycarbonyl metomidate: Studies in a lipopolysaccharide inflammatory model of sepsis. Anesthesiology. 2015;123:368–76.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera